Download PDF
Arthritis und Rheuma 2018; 38(01): 22-26
DOI: 10.1055/s-0038-1636987
Organbeteiligung bei Rheuma
Schattauer GmbH

Rheuma und chronisch-entzündliche Darmerkrankungen

Rheumatism and inflammatory bowel diseases (IBD)
B. Bokemeyer
1   Gastroenterologische Gemeinschaftspraxis Minden
,
H.-J. Lakomek
2   Klinik für Rheumatologie und Universitätsklinik für Geriatrie, Johannes Wesling Klinikum Minden
› Author Affiliations
Further Information

Publication History

Publication Date:
04 April 2018 (online)

    Permissions and Reprints

Zusammenfassung

Spondyloarthritiden unterteilen sich hinsichtlich der Skelettmanifestation in eine periphere und axiale Form und finden sich bei Morbus Crohn und Colitis ulcerosa in ca. 25 % der Fälle als extraintestinale Manifestation. Die Diagnostik beruht auf typischen klinischen Merkmalen bei der axialen Spondyloarthritis. Hier findet sich ein tiefer entzündlicher Rückenschmerz und eine Sakroiliitis (konventionell-radiologisch oder mittels MRT nachgewiesen). Die Diagnose der peripheren Beteiligung bei Spondyloarthritis richtet sich nach dem klinischen Bild unter Berücksichtigung von Krankheitsmerkmalen wie Arthritis, Enthesitis und Daktylitis. Im Vordergrund der Therapie der Spondyloarthritiden mit chronisch- entzündlicher Darmerkrankung (CED) steht neben der intensiven Physiotherapie die kurzfristige Gabe von nichtsteroidalen Antirheumatika (NSAR), da bei längerer Einnahme von NSAR Schübe der CED ausgelöst werden können. Cox-2-Hemmer können hier eine Alternative zu den herkömmlichen NSAR darstellen. Bei der axialen Spondyloarthritis sind Sulfasalazin und MTX weniger wirksam, weshalb möglichst früh eine Therapie mit Biologika gestartet werden sollte. Bei der Spondyloarthritis mit einer peripheren Arthritis können initial kurzfristig verabreichte orale Kortikosteroide effektiv sein, bei persistierender Arthritis kann eine Behandlung mit Sulfasalazin oder Methotrexat versucht werden. Auch für diese Verlaufsformen der Spondylo - arthritis gilt, bei therapieresistenten Fällen möglichst frühzeitig Biologika einzusetzen.

Summary

Both peripheral and axial arthropathies, which belong to the spondyloarthritis (SpA) group of conditions, occur as extra-intestinal manifestations (EIM) of Crohn’s disease (CD) and ulcerative colitis (UC) in 25 % of the cases. Diagnosis of axial SpA is based on typical clinical features such as inflammatory low back pain and sacroiliitis evidenced by magnetic resonance- or conventional radiographic imaging. Diagnosis of peripheral arthropathy is based on clinical signs of arthritis, enthesitis or dactylitis. Therapy of spondyloarthritis associated with IBD focusses on an intense physical therapy and a short-term application of non-steroidal antiinflammatory drugs (NSAIDs). As the longterm use of NSAID may trigger an exacerbation of IBD Coxibs represent an appropriate alternative. Sulfasalazine and methotrexate are of limited efficacy in the treatment of axial spondyloarthritis, so that the administration of suitable biologicals should be initiated as early as possible. Short-term oral corticosteroids can be effective in the treatment of a peripheral spondyloarthritis, in persistent arthritis a sulfasalazine- or methotrexate- therapy can be considered a promising option. The early use of biologicals is recommended in all cases resistant to the conventional therapeutic approach.

Schlüsselwörter

Chronisch-entzündliche Darmerkrankungen - Spondyloarthritis - extraintestinale Manifestationen - Colitis ulcerosa - M. Crohn

Keywords

Inflammatory bowel disease - spondyloarthritis - extra-intestinal manifestations - ulcerative colitis - Crohn´s disease
 

  • Literatur

  • 1 Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new?. Current rheumatology reports 2012; 14: 422-427.
    CrossrefPubMedGoogle Scholar
  • 2 Bolten W. Rheuma und Magen-Darm-Trakt. 1996; 93: A-380.
    Google Scholar
  • 3 Bonner GF, Fakhri A, Vennamaneni SR. A longterm cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflammatory bowel diseases 2004; 10: 751-757.
    CrossrefPubMedGoogle Scholar
  • 4 Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflammatory bowel diseases 2009; 15: 1915-1924.
    CrossrefPubMedGoogle Scholar
  • 5 Cipolla G, Crema F, Sacco S. et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacological research: the official journal of the Italian Pharmacological Society 2002; 46: 1-6.
    CrossrefPubMedGoogle Scholar
  • 6 de Vlam K, Mielants H, Cuvelier C. et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. The Journal of rheumatology 2000; 27: 2860-2865.
    PubMedGoogle Scholar
  • 7 De Vos M, Mielants H, Cuvelier C. et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-1703.
    CrossrefPubMedGoogle Scholar
  • 8 El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. The American journal of gastroenterology 2006; 101: 311-317.
    CrossrefPubMedGoogle Scholar
  • 9 Felder JB, Korelitz BI, Rajapakse R. et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. The American journal of gastroenterology 2000; 95: 1949-1954.
    CrossrefPubMedGoogle Scholar
  • 10 Fernando VelosoTavarela. Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?. World J Gastroenterol 2011; 17: 2702-2707.
    CrossrefPubMedGoogle Scholar
  • 11 Ferraz MB, Tugwell P, Goldsmith CH, Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of rheumatology 1990; 17: 1482-1486.
    PubMedGoogle Scholar
  • 12 Fiehn C, Herzer P, Holle J. et al. Klug entscheiden in der Rheumatologie. Dt Ärztebl. 2016 113. (24).
    PubMedGoogle Scholar
  • 13 Fornaciari G, Salvarani C, Beltrami M. et al. Muscoloskeletal manifestations in inflammatory bowel disease. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2001; 15: 399-403.
    PubMedGoogle Scholar
  • 14 Generini S, Giacomelli R, Fedi R. et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Annals of the rheumatic diseases 2004; 63: 1664-1669.
    CrossrefPubMedGoogle Scholar
  • 15 Harbord M, Annese V, Vavricka SR. European Crohn’s and Colitis Organisation. et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis 2016; 10: 239-254.
    CrossrefPubMedGoogle Scholar
  • 16 Herfarth H, Obermeier F, Andus T. et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn’s disease. The American journal of gastroenterology 2002; 97: 2688-2690.
    CrossrefPubMedGoogle Scholar
  • 17 Jostins L, Ripke S, Weersma RK. et al. Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124.
    CrossrefPubMedGoogle Scholar
  • 18 Kavanaugh A, Puig L, Gottlieb AB. PSUMMIT 1 Study Group. et al. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken) 2015; 67: 1739-1749.
    CrossrefPubMedGoogle Scholar
  • 19 Lakatos L, Pandur T, David G. et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 09: 2300-2307.
    CrossrefPubMedGoogle Scholar
  • 20 Marzo-Ortega H, McGonagle D, O’Connor P, Emery P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Annals of the rheumatic diseases 2003; 62: 74-76.
    CrossrefPubMedGoogle Scholar
  • 21 McInnes KAIB, 1 Gottlieb AB, Puig L. PSUMMIT 1 Study Group. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 31: 780-789.
    Google Scholar
  • 22 Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42: 387-391.
    CrossrefPubMedGoogle Scholar
  • 23 Orlando A, Orlando R, Ciccia F. et al. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. Ann Rheum Dis 2017; 76: e31 doi: 10.1136/annrheumdis-2016–211011. Epub 2017 Jan 17.
    CrossrefPubMedGoogle Scholar
  • 24 Ossum AM, Palm Ø, Lunder AK. et al. IBSEN study group. J Crohns Colitis. 2017; 13 doi 10.1093/ecco-jcc/jjx126.
    PubMedGoogle Scholar
  • 25 Palm Ø, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). The Journal of rheumatology 2002; 29: 511-515.
    PubMedGoogle Scholar
  • 26 Peeters H, Vander Cruyssen B, Mielants H. et al. Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. Journal of gastroenterology and hepatology 2008; 23: 132-137.
    PubMedGoogle Scholar
  • 27 Poddubnyy D, Rudwaleit M, Haibel H. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Annals of the rheumatic diseases 2012; 71: 1616-1622.
    CrossrefPubMedGoogle Scholar
  • 28 Queiro R, Maiz O, Intxausti J. et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clinical rheumatology 2000; 19: 445-449.
    CrossrefPubMedGoogle Scholar
  • 29 Reveille JD. Genetics of spondyloarthritis beyond the MHC. Nature reviews. Rheumatology 2012; 08: 296-303.
    Google Scholar
  • 30 Ritchlin C, Rahman P, Kavanaugh A. PSUMMIT 2 Study Group. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-999.
    CrossrefPubMedGoogle Scholar
  • 31 Rudwaleit M, van der Heijde D, Landewé R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Annals of the rheumatic diseases 2009; 68: 777-783.
    CrossrefPubMedGoogle Scholar
  • 32 Rudwaleit M, Van der Heijde D, Landewé R. et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
    CrossrefPubMedGoogle Scholar
  • 33 S3-Leitlinie “Diagnostik und Therapie des Morbus Crohn” 2014. AWMF-Register-Nr.: 021/004.
    Google Scholar
  • 34 Salvarani C, Vlachonikolis IG, van der Heijde DM. European Collaborative IBD Study Group. et al. Musculoskeletal manifestations in a populationbased cohort of inflammatory bowel disease patients. Scandinavian journal of gastroenterology 2001; 36: 1307-1313.
    CrossrefPubMedGoogle Scholar
  • 35 Sandborn WJ, Stenson WF, Brynskov J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2006; 04: 203-211.
    CrossrefPubMedGoogle Scholar
  • 36 Steer S, Jones H, Hibbert J. et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. The Journal of rheumatology 2003; 30: 518-522.
    PubMedGoogle Scholar
  • 37 Van den Bosch F, Kruithof E, De Vos M. et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-1822.
    CrossrefPubMedGoogle Scholar
  • 38 Vavricka SR, Rogler G, Gantenbein C. et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2015; 21: 1794-1800.
    CrossrefPubMedGoogle Scholar
  • 39 Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Annals of the rheumatic diseases 2006; 65: 423-432.
    CrossrefPubMedGoogle Scholar